Compare Li Auto Inc (LI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Moderna, Inc. — how do they compare? Li Auto Inc trades at $11.53 (market cap $10.71B), while Moderna, Inc. trades at $224.78 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 7.3× Li Auto Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Moderna, Inc. for 59 Days on average.
| LI | MRNA | |
|---|---|---|
Market Cap | $10.71B | $78.65B |
Volume | 1,781,143 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $203.46 |
52-Week Low | $10.69 | $22.36 |
Typical Hold Time | 101 Days | 59 Days |
Enterprise Value | $139.58M | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.54, down 5.0% recently and near 52-week lows amid weak delivery numbers. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $144.5B in 2024 to $112.3B in 2025 and negative net income margins. Recent news highlights September deliveries of 31,817 vehicles and new model launches like the Li i9 SUV.
Outlook remains challenging with intense EV competition and cash flow concerns, though analyst consensus suggests 32% upside to $15.18 target. Key risks include execution on new models and Chinese market volatility, while the strong balance sheet provides some stability for patient investors.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
